Blomgren Fredrik, Rodin Alexander, Chrobak Wojciech, Pacut Dawid Wojciech, Swenson Jan, Ermilova Inna
Department of Physics, Chalmers University of Technology Fysikgränd 4 Göteborg 41258 Sweden
RSC Adv. 2022 May 4;12(21):13352-13366. doi: 10.1039/d2ra01963a. eCollection 2022 Apr 28.
In this work, possible effective mechanisms of cromolyn, atorvastatin and lovastatin on the cytotoxicity of Aβ(31-35) and Aβ(25-35) peptides were investigated by classical molecular dynamics and well-tempered metadynamics simulations. The results demonstrate that all the drugs affect the behavior of the peptides, such as their ability to aggregate, and alter their secondary structures and their affinity to a particular drug. Our findings from the computed properties suggest that the best drug candidate is lovastatin. This medicine inhibits peptide aggregation, adsorbs the peptides on the surface of the drug clusters, changes the secondary structure and binds to MET, which has been seen as the reason for the toxicity of the studied peptide sequences. Moreover, lovastatin is the drug which previously has demonstrated the strongest ability to penetrate the blood-brain barrier and makes lovastatin the most promising medicine among the three investigated drugs. Atorvastatin is also seen as a potential candidate if its penetration through the blood-brain barrier could be improved. Otherwise, its properties are even better than the ones demonstrated by lovastatin. Cromolyn appears to be less interesting as an anti-aggregant from the computational data, in comparison to the two statins.
在这项工作中,通过经典分子动力学和加权平均元动力学模拟研究了色甘酸钠、阿托伐他汀和洛伐他汀对Aβ(31 - 35)和Aβ(25 - 35)肽细胞毒性的可能有效机制。结果表明,所有药物都会影响肽的行为,比如它们的聚集能力,改变其二级结构以及它们与特定药物的亲和力。我们从计算属性得出的研究结果表明,最佳候选药物是洛伐他汀。这种药物抑制肽聚集,将肽吸附在药物簇表面,改变二级结构并与MET结合,而MET被认为是所研究肽序列产生毒性的原因。此外,洛伐他汀是此前已证明具有最强血脑屏障穿透能力的药物,这使得洛伐他汀成为三种被研究药物中最有前景的药物。如果阿托伐他汀对血脑屏障的穿透能力能够提高,它也被视为一个潜在候选药物。否则,其性能甚至优于洛伐他汀所展示的性能。与两种他汀类药物相比,从计算数据来看,色甘酸钠作为一种抗聚集剂似乎不太有吸引力。